Key Developments: Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

40.86USD
19 Dec 2014
Price Change (% chg)

$2.24 (+5.80%)
Prev Close
$38.62
Open
$38.33
Day's High
$41.25
Day's Low
$37.85
Volume
715,556
Avg. Vol
280,177
52-wk High
$41.25
52-wk Low
$14.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

Chimerix Inc and ContraVir Pharmaceuticals establish strategic collaboration for antiviral drug candidate CMX157
Thursday, 18 Dec 2014 06:00am EST 

Chimerix Inc and ContraVir Pharmaceuticals, Inc:Says that they have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.CMX157 is a potent analog of the antiviral drug tenofovir DF (Viread).Says ContraVir licenses CMX157 from Chimerix in exchange for an upfront payment consisting of 120,000 shares of ContraVir preferred stock with a stated value of $1.2 mln.Says in addition, Chimerix is eligible to receive up to about $20 mln in clinical, regulatory and initial commercial milestones in the United States and Europe, as well as royalties and additional milestones based on commercial sales in those territories.  Full Article

Chimerix Inc's Brincidofovir selected for use in Ebola clinical trial in West Africa by International Consortium
Thursday, 13 Nov 2014 12:30pm EST 

Chimerix Inc:Says its investigational broad-spectrum antiviral brincidofovir has been selected as one of two investigational agents to be evaluated in a clinical study in patients with confirmed Ebola Virus Disease in west Africa.Chimerix and the University of Oxford are in the process of finalizing a definitive agreement for supplying brincidofovir for the planned clinical trial.  Full Article

Chimerix Inc prices public offering of common stock
Thursday, 30 Oct 2014 06:37pm EDT 

Chimerix Inc:Prices of underwritten public offering of 3,650,000 shares of its common stock at price to public of $29 per share.Gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be about $105.9 million.Expects expected to close on or about Nov. 5.Anticipates using net proceeds from offering to fund its research and development efforts and for general corporate purposes, including working capital.Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for offering.Cowen and Company, LLC, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as co-lead managers for offering.Cantor Fitzgerald & Co. and Brean Capital, LLC are acting as co-managers for offering.Says that it has granted underwriters 30-day option to purchase up to aggregate of 547,500 additional shares of common stock.  Full Article

Chimerix Inc announces commencement of public offering of common stock
Wednesday, 29 Oct 2014 04:55pm EDT 

Chimerix Inc:Intends to offer and sell, subject to market and other conditions, about $105,000,000 of its common stock in an underwritten public offering.In connection with this offering, Chimerix expects to grant the underwriters a 30-day option to purchase up to about $15,750,000 of additional shares of its common stock.Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, and Cowen and Company, LLC, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as co-lead managers for the offering.Offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering.Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.  Full Article

Chimerix and BARDA announce continued partnership in the development of Brincidofovir for Smallpox
Tuesday, 2 Sep 2014 08:01am EDT 

Chimerix Inc:Says award of $17.0 mln through the extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of its broad spectrum antiviral brincidofovir as a medical countermeasure to treat smallpox.Receives the initial award in February 2011 which supported early research and development of brincidofovir in animal models of smallpox.Contract extension provides an additional $17.0 million to Chimerix for a period of 15 months, and will support Phase 3 trials expected to initiate in the second half of 2014.  Full Article

Chimerix Inc announces completion of public offering of common stock
Tuesday, 27 May 2014 04:01pm EDT 

Chimerix Inc:Completion of underwritten public offering of 8,395,000 shares of its common stock, including 1,095,000 shares sold pursuant to full exercise of option previously granted to the underwriters to purchase additional shares of common stock.All of shares were offered by Chimerix at a price to the public of $14.22 per share.Gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, were about $119.4 mln.Chimerix anticipates using net proceeds to fund its research and development efforts and for general corporate purposes, including working capital.Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC acted as joint book-running managers for offering.Cowen and Company, LLC acted as co-lead manager for the offering, and William Blair & Company, L.L.C. and Canaccord Genuity Inc. acted as co-managers for the offering.  Full Article

Chimerix Inc announces commencement of public offering of common stock
Monday, 19 May 2014 04:01pm EDT 

Chimerix Inc:Says it is offering to sell 6,200,000 shares of its common stock in an underwritten public offering.In connection with this offering, Chimerix will also grant to underwriters a 30-day option to purchase up to an aggregate of 930,000 additional shares of common stock.Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering and Cowen and Company, LLC is acting as co-lead manager for the offering.The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.  Full Article

Chimerix Inc appoints new chief executive officer and president
Wednesday, 9 Apr 2014 09:00am EDT 

Chimerix Inc:Appoints M. Michelle Berrey to the position of president and chief executive officer.Berrey succeeds Kenneth I. Moch following his resignation from that role to pursue other interests.In addition Berrey will continue to serve as Chimerix's Chief Medical Officer.  Full Article

Chimerix Inc to provide brincidofovir to Josh Hardy as first patient in new open-label study in patients with adenovirus infections
Tuesday, 11 Mar 2014 07:57pm EDT 

Chimerix Inc:Reaches agreement with U.S. Food and Drug Administration (FDA) for immediate initiation of pilot trial of open-label brincidofovir for treatment of adenovirus infections in immunocompromised patients.FDA has committed to work expeditiously with Chimerix on design of pivotal Phase 3 study that would be continuation of this pilot study.Josh Hardy's story brought to public attention the often-devastating impact of adenovirus infection, and helped accelerate a discussion between FDA and Chimerix regarding need for additional clinical development to assess brincidofovir's potential in adenovirus infection.This study is expected to begin with Josh Hardy as the first patient enrolled on March 12.  Full Article

Chimerix Inc Announces Completion Of Secondary Offering Of Common Stock
Wednesday, 23 Oct 2013 04:54pm EDT 

Chimerix, Inc announced that the completion of an underwritten public offering of 2,476,995 shares of its common stock at a price to the public of $16.50 per share. All of the shares were sold by certain existing stockholders. Chimerix did not receive any proceeds from the sale of the shares. The principal purposes of the offering are to facilitate an orderly distribution of shares and to increase the Company's public float. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 371,549 shares of common stock to cover over-allotments. Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. and Canaccord Genuity Inc. are acting as co-managers for the offering.  Full Article

Chimerix antiviral to be tested in West African Ebola trial

- Chimerix Inc said its experimental broad-spectrum antiviral was one of two agents to be tested in a trial in confirmed Ebola patients in West Africa.

Search Stocks